Ex-Synta chief Whitaker lands at Valeant; GW Pharma raising $180M;

@FierceBiotech: Activists get their way as Ariad CEO Berger steps down. Article | Follow @FierceBiotech

@JohnCFierce: I asked CRISPR Tx CEO Novak if he was prepping an IPO. (Answer: all options open) Felt damn silly even asking, but you have to these days. | Follow @JohnCFierce

@DamianFierce: Zymoquizyme got robbed. RT @CarlyHFierce What's in a (drug) name? We asked the #FierceMadness champs. More | Follow @DamianFierce

> Former Synta ($SNTA) CEO Anne Whitaker has joined Valeant Pharmaceuticals ($VRX), stepping in as an executive vice president. More

> The FDA accepted AbbVie ($ABBV) and Biogen's ($BIIB) application for the long-acting multiple sclerosis treatment daclizumab. News

> Viking Therapeutics ($VKTX) priced a $24 million IPO, moving 3 million shares at $8 each. Item

> The U.K.'s GW Pharmaceuticals ($GWPH) is raising $180 million to push its cannabis-derived epilepsy drug forward. Story

Medical Device News

@FierceMedDev: NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Story | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. More | Follow @VarunSaxena2

@EmilyWFierce: #France's Labco looks to make market entree with €545 million IPO. Article | Follow @EmilyWFierce

> Philips ramping up CT scan production following €100M quality improvement plan at Cleveland facility. More

> Kaiser backs startup in $12.5M round to speed healthcare data integration. Story

> NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Article

Pharma News

@FiercePharma: $GSK buoyed by early numbers on Anoro, Breo DTC campaigns. More | Follow @FiercePharma

@EricPFierce: Manufacturing plant cost baked into $2.5B Biogen CEO says it will cost to develop Alzheimer's drug. Item | Follow @EricPFierce

@CarlyHFierce: What's in a (drug) name? We asked the #FierceMadness champs. Article | Follow @CarlyHFierce

> AstraZeneca scores fast-track FDA review for big new Brilinta use. News

> After topping Q1 estimates, Valeant hikes guidance on Salix buy. Story

> Express Scripts: Fight against cancer drug prices 'much bigger' than hep C. More

Biotech Research News

> Mayo Clinic study finds a potential Achilles' heel for HER2-positive cancer. Story

> Better than RNAi? Emory team modifies CRISPR-Cas9 tech for viral infections. News

> Yale collaborators use gene editing tech to fix a cystic fibrosis mutation. Article

> International team opens a 'new frontier' in diabetes research. More

> Google's Calico continues its partnering romp on aging R&D with Buck collaboration. More

Diagnostics News

> Researchers show Adaptive's next-gen sequencing tech can diagnose recurrent Hodgkin lymphoma. Story

> Veracyte unveils $40M private placement to generate cash for R&D. Article

> Biocartis charges ahead with $109M IPO to fuel product development. More

> Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. News

> Roche charges ahead with diagnostics R&D after sealing Foundation deal. Report

Pharma Marketing News

> Time for an asthma check, doc? AstraZeneca-sponsored EHR reminders will tell you. More

> GSK buoyed by early numbers on Anoro, Breo DTC campaigns. News

> Merck could be in for big Januvia boost, thanks to 'completely balanced' heart data. Report

> AbbVie says disappointing Viekira sales numbers are misleading. Article

> Pharma earns failing marks for integrity, but it beats advertising. Story

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.